Yin Y, Wang M, Liu M, et al. - This study was undertaken to investigate the efficacy and safety of IL-17 inhibitors in patients with active ankylosing spondylitis. Researchers conducted a systematic review of the literature for randomized controlled trials concerning IL-17 inhibitors in patients with ankylosing spondylitis. They applied meta-analyses to ascertain the effectiveness and safety of the IL-17 inhibitors in the treatment of these patients. This analysis included six phase III randomized, double-blind, placebo-controlled trials involving a total of 1,733 patients (1,153 patients received IL-17 inhibitors, including secukinumab or ixekizumab, whereas 580 patients received a placebo as comparators). The data showed that in the treatment of active ankylosing spondylitis, IL-17 inhibitors produced favorable response rates but an increased risk of non-severe infections.